Boule appoints Johan Folkunger as CEO
He succeeds Simonetta Tumbiolo and starts June 22, 2026.
See the latest news and media coverage for Boule. We track all announcements, press releases, and industry mentions in real time, all in one place.
Hematology and clinical chemistry diagnostics provider
boule.comLast updated
In short: Boule Diagnostics underwent a leadership transition, naming Johan Folkunger as CEO, while facing financial challenges and reporting quarterly losses.
He succeeds Simonetta Tumbiolo and starts June 22, 2026.
She takes office on June 1, 2026 to ensure continuity while the board recruits a permanent CEO.
The AGM approved 2025 financials, re-elected directors, and authorized share issuance.
Net sales decreased to 101.6 MSEK by 10%. Organic growth 3%. Adjusted EBIT -1.4 MSEK. Positive cash flow 17.7 MSEK.
Boule Diagnostics AB ( (SE:BOUL) ) just unveiled an announcement.
The diagnostics company Boule Diagnostics has appointed Simonetta Tumbiolo, currently Chief Commercial Officer Diagnostic, as acting CEO from June 1.
At the Annual General Meeting 2026 (the "AGM") it was resolved to adopt the balance sheets and profit and loss statements for the parent company...
The medical technology company Boule Diagnostics reports a net result after tax of -14.6 million kronor for the first quarter of 2026 (-10.3). The result per...
Track Boule and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Boule and other trending companies.